A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
This is a multicenter, multinational, double-blind, 1:1 randomized, parallel-group,
equivalence Phase 3 study to compare the efficacy and safety of MB02 plus chemotherapy
(carboplatin and paclitaxel) versus Avastin® plus chemotherapy (carboplatin and paclitaxel)
in subjects with Stage IIIB/IV non-squamous NSCLC